<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159642">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01758094</url>
  </required_header>
  <id_info>
    <org_study_id>24122012</org_study_id>
    <nct_id>NCT01758094</nct_id>
  </id_info>
  <brief_title>Plasma RBP Levels in Patients With Idiopathic Hypogonadotrophic Hypogonadism</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gulhane School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gulhane School of Medicine</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study was to demonstrate the RBP4 levels, association of RBP4 with
      insulin resistance and influence of testosterone treatment on this cytokine in patients with
      idiopathic hypogonadotropic hypogonadism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Retinol binding protein 4, hs-CRP levels in patients with idiopathic hypogonadotrophic hypogonadism</measure>
    <time_frame>2008-2012</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of testosterone treatment on retinol binding globulin 4 and hs-CRP levels in patients with hypogodotrophic hypogonadism</measure>
    <time_frame>2008-2012</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Idiopathic Hypogonadotropic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Hypogonadotropic hypogonadism patients</arm_group_label>
    <description>Treatment naive 25 patients with idiopathic hypogonadotrophic hypogonadism</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sustanon 250 mg ampule  (Testosterone esters)</intervention_name>
    <description>Drug used for treatment of hypogonadism</description>
    <arm_group_label>Hypogonadotropic hypogonadism patients</arm_group_label>
    <other_name>No name</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hypogonadotrophic hypogonadism
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        decreased serum testosterone concentration below the normal range (serum T &lt; 300ng/dL),
        FSH and LH levels within or below the normal range, absence of a pituitary or hypothalamic
        mass lesions on MRI, presence of gonadotropin response to repetitive doses of GnRH, normal
        smell test and normal karyotypes

        Exclusion Criteria:

        previous androgen treatment, history of smoking, presence of bilateral anorchia,
        intellectual deficiency, diabetes mellitus, arterial hypertension or dyslipoproteinemia,
        medication of any kind and drug abuse. Because of possible confounding effects, patients
        with other hormone deficiencies were excluded.

        -
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aydogan Aydogdu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gulhane School of Medicine, Department of Endocrinology and Metabolism</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gulhane School of Medicine Dep. of Endocrinology and Metabolism</name>
      <address>
        <city>Ankara</city>
        <zip>06018</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 1, 2013</lastchanged_date>
  <firstreceived_date>December 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gulhane School of Medicine</investigator_affiliation>
    <investigator_full_name>Aydogan Aydogdu</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>hypogonadism</keyword>
  <keyword>Retinol binding globulin 4</keyword>
  <keyword>Testosterone treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
